Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields -

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Gilead Sciences, Inc. (NASDAQ:GILD)

Dividend Yield: 3.64%
RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $74 to $75 on Oct. 4. This analyst has an accuracy rate of 61%.
Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 76%.
Recent News: On Oct. 2, Dr. Reddy’s signed voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
Benzinga Pro's real-time newsfeed alerted to latest GILD news.

GSK plc (NYSE:GSK)

Dividend Yield: 3.94%
Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 68%.
Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%
Recent News: The U.S. government has granted $72 million to European pharma giants GSK Plc, Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.
Benzinga Pro's real-time newsfeed alerted to latest GSK news.

AbbVie Inc. (NYSE:ABBV)

Dividend Yield: 3.19%
Morgan Stanley analyst Terence Flynn maintained an Overweight rating and boosted the price target from $211 to $218 on Aug. 12. This analyst has an accuracy rate of 70%.
Wells Fargo analyst Mohit Bansal maintained an Overweight rating and raised the price target from $200 to $205 on July 26. This analyst has an accuracy rate of 75%.
Recent News: AbbVie will announce its third-quarter financial results on Wednesday, Oct. 30, before the opening bell.
Benzinga Pro’s charting tool helped identify the trend in ABBV stock.